Logo image of GRFS

GRIFOLS SA-ADR (GRFS) Stock Price, Quote, News and Overview

NASDAQ:GRFS - Nasdaq - US3984384087 - ADR - Currency: USD

7.45  -0.08 (-1.06%)

After market: 7.5 +0.05 (+0.67%)

GRFS Quote, Performance and Key Statistics

GRIFOLS SA-ADR

NASDAQ:GRFS (2/21/2025, 8:24:28 PM)

After market: 7.5 +0.05 (+0.67%)

7.45

-0.08 (-1.06%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High9.96
52 Week Low5.3
Market Cap5.06B
Shares679.63M
Float284.19M
Yearly Dividend0
Dividend YieldN/A
PE33.86
Fwd PE7.85
Earnings (Next)02-26 2025-02-26/amc
IPO05-17 2006-05-17


GRFS short term performance overview.The bars show the price performance of GRFS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 -10

GRFS long term performance overview.The bars show the price performance of GRFS in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30

The current stock price of GRFS is 7.45 USD. In the past month the price decreased by -0.27%. In the past year, price decreased by -18.4%.

GRIFOLS SA-ADR / GRFS Daily stock chart

GRFS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About GRFS

Company Profile

GRFS logo image Grifols SA engages in the production of plasma derivatives. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 23,744 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.

Company Info

GRIFOLS SA-ADR

Parque Empresarial Can Sant Joan, Avinguda de la Generalitat, 152-158

Sant Cugat del Valles BARCELONA 08174 ES

CEO: Raimon Grifols Roura

Employees: 23505

Company Website: https://www.grifols.com/

Investor Relations: https://www.grifols.com/en/investors

Phone: 34935710000

GRIFOLS SA-ADR / GRFS FAQ

What is the stock price of GRIFOLS SA-ADR today?

The current stock price of GRFS is 7.45 USD. The price decreased by -1.06% in the last trading session.


What is the ticker symbol for GRIFOLS SA-ADR stock?

The exchange symbol of GRIFOLS SA-ADR is GRFS and it is listed on the Nasdaq exchange.


On which exchange is GRFS stock listed?

GRFS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for GRIFOLS SA-ADR stock?

21 analysts have analysed GRFS and the average price target is 14.18 USD. This implies a price increase of 90.4% is expected in the next year compared to the current price of 7.45. Check the GRIFOLS SA-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GRIFOLS SA-ADR worth?

GRIFOLS SA-ADR (GRFS) has a market capitalization of 5.06B USD. This makes GRFS a Mid Cap stock.


How many employees does GRIFOLS SA-ADR have?

GRIFOLS SA-ADR (GRFS) currently has 23505 employees.


What are the support and resistance levels for GRIFOLS SA-ADR (GRFS) stock?

GRIFOLS SA-ADR (GRFS) has a support level at 6.95 and a resistance level at 7.46. Check the full technical report for a detailed analysis of GRFS support and resistance levels.


Is GRIFOLS SA-ADR (GRFS) expected to grow?

The Revenue of GRIFOLS SA-ADR (GRFS) is expected to grow by 8.13% in the next year. Check the estimates tab for more information on the GRFS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy GRIFOLS SA-ADR (GRFS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GRIFOLS SA-ADR (GRFS) stock pay dividends?

GRFS does not pay a dividend.


When does GRIFOLS SA-ADR (GRFS) report earnings?

GRIFOLS SA-ADR (GRFS) will report earnings on 2025-02-26, after the market close.


What is the Price/Earnings (PE) ratio of GRIFOLS SA-ADR (GRFS)?

The PE ratio for GRIFOLS SA-ADR (GRFS) is 33.86. This is based on the reported non-GAAP earnings per share of 0.22 and the current share price of 7.45 USD. Check the full fundamental report for a full analysis of the valuation metrics for GRFS.


What is the Short Interest ratio of GRIFOLS SA-ADR (GRFS) stock?

The outstanding short interest for GRIFOLS SA-ADR (GRFS) is 1.1% of its float. Check the ownership tab for more information on the GRFS short interest.


GRFS Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to GRFS. When comparing the yearly performance of all stocks, GRFS is a bad performer in the overall market: 82.73% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

GRFS Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to GRFS. There are concerns on the financial health of GRFS while its profitability can be described as average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GRFS Financial Highlights

Over the last trailing twelve months GRFS reported a non-GAAP Earnings per Share(EPS) of 0.22. The EPS increased by 162.5% compared to the year before.


Industry RankSector Rank
PM (TTM) 2.05%
ROA 0.71%
ROE 2.69%
Debt/Equity 1.65
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%12.24%
EPS 1Y (TTM)162.5%
Revenue 1Y (TTM)-13.25%

GRFS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 74% to GRFS. The Buy consensus is the average rating of analysts ratings from 21 analysts.

For the next year, analysts expect an EPS growth of 14.73% and a revenue growth 8.13% for GRFS


Ownership
Inst Owners33.7%
Ins Owners6.01%
Short Float %1.1%
Short Ratio3.72
Analysts
Analysts74.29
Price Target14.18 (90.34%)
EPS Next Y14.73%
Revenue Next Year8.13%